Prostate-specific Membrane Antigen Expression Is Associated with Aggressive Clinicopathological Features and Short-term Incomplete Response to Initial Radioiodine Therapy in Papillary Thyroid Carcinoma: A Retrospective Single-Center Cohort Study
This retrospective study demonstrates that endothelial expression of prostate-specific membrane antigen (PSMA) in papillary thyroid carcinoma is significantly associated with aggressive clinicopathological features and independently predicts a short-term incomplete response to initial radioiodine therapy.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Thyroid cancer is a disease that often moves slowly, allowing doctors to treat it successfully with surgery and a specific type of radiation called radioiodine therapy. This treatment works because the remaining thyroid cells, and the cancer cells that might have spread, naturally absorb iodine. Once they take it in, the radiation destroys them from the inside. However, for a significant number of patients, this standard approach does not work as well as hoped. The cancer cells either do not absorb the iodine or stop responding to it, leaving the disease to grow or return. To understand why this happens, scientists look at the tiny blood vessels that feed the tumor. Just as a growing city needs new roads and pipes to support its expansion, a growing tumor needs a fresh network of blood vessels to bring it oxygen and nutrients. This process of building new blood vessels is called angiogenesis, and it is a critical step that allows cancer to become more aggressive and harder to treat.
In a recent study, researchers set out to examine a specific protein found on the surface of these new blood vessels. This protein, known as prostate-specific membrane antigen, or PSMA, is well-known for its presence in prostate cancer, but scientists have also found it in the blood vessels of other cancers, including thyroid cancer. The team wanted to know if the amount of this protein present in the blood vessels of thyroid tumors could tell them something about how aggressive the cancer was and whether the patient would respond well to the initial radioiodine treatment. They focused on a group of 241 patients who had undergone surgery to remove their thyroid glands and were then treated with radioiodine. By looking at tissue samples under a microscope, the researchers checked how much of this protein was present in the blood vessels surrounding the tumor cells.
The investigation revealed a clear pattern. The protein was found exclusively in the blood vessels that fed the tumor; it was not present in the cancer cells themselves, nor in healthy thyroid tissue. In about 80 percent of the patients, the researchers could detect this protein. When they compared the amount of protein to the characteristics of the tumors, a strong link emerged. Patients whose tumors had higher levels of this protein tended to have larger tumors, cancers that had spread to multiple spots within the thyroid, and tumors that had broken through the thyroid's outer capsule or invaded nearby tissues. These are all signs of a more aggressive disease. Furthermore, the study found that patients with higher levels of this protein were significantly less likely to have a successful response to their first round of radioiodine therapy. While only about 12 percent of patients with low levels of the protein had an incomplete response, that number jumped to 50 percent for those with high levels.
The researchers used statistical methods to confirm that this connection was not just a coincidence. Even when they accounted for other known risk factors, such as the size of the tumor or the presence of cancer in the lymph nodes, the level of this protein remained a strong, independent predictor of whether the treatment would fail to clear the disease in the short term. This suggests that the protein serves as a marker for a tumor that is biologically more active and has built a richer, more complex network of blood vessels to support its growth. The study also looked specifically at patients who were already considered high-risk for recurrence. In this group, the presence of the protein, along with other markers of rapid cell division, continued to predict a poorer response to treatment.
Despite these clear findings, the authors are careful to note that this study does not yet prove that the protein causes the treatment failure, nor does it suggest that doctors should change how they treat patients based on this test alone. The research was retrospective, meaning it looked back at data from patients who had already been treated, and it was conducted at a single medical center. The follow-up period was relatively short, covering only six to twelve months after treatment, which is enough to see an initial response but not enough to determine if the cancer will return years later. The researchers emphasize that while the protein appears to be a useful signpost for identifying tumors that might be harder to treat, more studies are needed to confirm these results in larger groups of people over a longer period. Until then, this discovery offers a new way to look at the biology of thyroid cancer, highlighting the importance of the blood vessels that feed it and providing a potential tool for better understanding which patients might need closer monitoring or different strategies in the future.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.